A recent research line of our department aimed at defining mechanisms of drug resistance. Indeed, despite the remarkable advances in oncology, cancer resistance to available therapies represents one of the main challenges in cancer treatment and research nowadays. The reasons are likely to be multifactorial and defining the mechanisms responsible for drug resistance might provide novel therapeutic strategies as well as further precious knowledge on cancer biology. Therefore, unveiling mechanisms of drug resistance is a main focus of DEO researchers, which enabled to gain important insights in the field, such as the identification of Sunitinib drug and endocrine treatments.
Identification of a resistance mechanism to endocrine therapies
Identification of mitochondrial ribosomes as effectors of MYC in B-cell lymphomas and pre-clinical targeting of their activity with the antibiotic Tigecycline
